Announcement on Serious Abnormal Fluctuations in Stock Trading
Filed with SSE · · 3 pages · Chinese
Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Earlier from Chengdu Easton Biopharmaceuticals
- Announcement on Cancellation of Some Special Accounts for Raised Funds
- Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for the Class 2 Modified New Drug - Amhydrocodone Paracetamol Extended-Release Tablets
- Announcement on Application for Comprehensive Credit Line and Provision of Mutual Guarantee by the Company and Its Subsidiary in 2026
Later from Chengdu Easton Biopharmaceuticals
- Announcement on Voluntary Disclosure of Obtaining a Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Implementation of Dividend Distribution for 2025
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on Canceling Some Restricted Stocks in the 2024 Restricted Stock Incentive Plan
- Announcement on Initially Repurchasing the Company's Shares through Call Auction
Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals